Get the Stockscreener App
5.55
3.65%
-0.21
After Hours:
5.55
Sage Therapeutics Inc stock is traded at $5.55, with a volume of 577.27K.
It is down -3.65% in the last 24 hours and down -30.71% over the past month.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
See More
Previous Close:
$5.76
Open:
$5.78
24h Volume:
577.27K
Relative Volume:
0.80
Market Cap:
$352.36M
Revenue:
$91.06M
Net Income/Loss:
$-503.14M
P/E Ratio:
-0.5595
EPS:
-9.92
Net Cash Flow:
$-424.74M
1W Performance:
+13.03%
1M Performance:
-30.71%
6M Performance:
-52.89%
1Y Performance:
-70.96%
1-Day Range:
$5.48
$5.91
1-Week Range:
$4.80
$5.91
52-Week Range:
$4.62
$28.26
Sage Therapeutics Inc Stock (SAGE) Company Profile
Name
Sage Therapeutics Inc
Sector
Industry
Phone
617-299-8380
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare SAGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
5.55 | 352.36M | 91.06M | -503.14M | -424.74M | -9.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-04-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-29-24 | Initiated | Citigroup | Sell |
| May-29-24 | Initiated | Robert W. Baird | Neutral |
| Apr-17-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Aug-08-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-08-23 | Downgrade | Goldman | Buy → Neutral |
| Aug-08-23 | Downgrade | Needham | Buy → Hold |
| Aug-07-23 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-07-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-07-23 | Downgrade | Stifel | Buy → Hold |
| Aug-07-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Mar-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Mar-31-22 | Initiated | Berenberg | Hold |
| Nov-02-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-16-21 | Downgrade | Citigroup | Buy → Neutral |
| Apr-07-21 | Initiated | Piper Sandler | Overweight |
| Feb-26-21 | Downgrade | Mizuho | Buy → Neutral |
| Feb-25-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Resumed | Raymond James | Mkt Perform |
| Jan-22-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-04-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-04-20 | Upgrade | Mizuho | Neutral → Buy |
| Dec-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-06-20 | Reiterated | H.C. Wainwright | Neutral |
| Sep-11-20 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-10-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-08-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-28-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-06-19 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-05-19 | Reiterated | Guggenheim | Buy |
| Dec-05-19 | Downgrade | SunTrust | Buy → Hold |
| Oct-30-19 | Initiated | H.C. Wainwright | Neutral |
| May-23-19 | Initiated | Wedbush | Outperform |
| Apr-25-19 | Initiated | Jefferies | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-11-18 | Initiated | Oppenheimer | Outperform |
View All
Sage Therapeutics Inc Stock (SAGE) Latest News
Rx Rundown: Novartis, Sage Therapeutics, Eli Lilly and more - MM+M Online
Sage Therapeutics announces board member retirement By Investing.com - Investing.com Nigeria
Sage Therapeutics announces board member retirement - Investing.com India
Sage Therapeutics' SWOT analysis: stock faces hurdles amid CNS pipeline setbacks By Investing.com - Investing.com South Africa
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - BioSpace
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit - GuruFocus.com
Sage Therapeutics' SWOT analysis: stock faces hurdles amid CNS pipeline setbacks - Investing.com
Q1 Earnings Forecast for Sage Therapeutics Issued By Wedbush - MarketBeat
Sage Therapeutics to end development of key therapy after a third trial failure - MSN
Sage Therapeutics, Inc. Sued for Securities Law ViolationsCon - GuruFocus.com
Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Rating of "Hold" by Analysts - MarketBeat
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More - MSN
Sage Therapeutics Inc Sued for Securities Law ViolationsConta - GuruFocus.com
Sage Therapeutics price target lowered to $4 from $7 at BofA - Yahoo Finance
Layoff Tracker: Sonata Therapeutics Laying Off 20 Employees, Changing Leadership - BioSpace
RBC Capital Upgrades Sage Therapeutics (SAGE) - MSN
Sage raised to sector perform by RBC in wake of drug failure - MSN
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study - Yahoo Finance
Sage Therapeutics (NASDAQ:SAGE) Upgraded to "Sector Perform" at Royal Bank of Canada - MarketBeat
Sage scraps dalzanemdor after disappointing trial results - The Pharma Letter
Sage Therapeutics' Experimental Drug for Huntington's Disease Fails Mid-Stage Trial - Medical Dialogues
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder - AOL
Sage’s Pipeline Prospects Narrow Further As Dalzanemdor Fails In Huntington’s - Citeline
Third trial failure is end-of-the-road for Sage's neurological drug - The Business Journals
Sage to abandon development of neurological disorder drug after multiple failures - Reuters.com
Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics - Benzinga
Needham & Company LLC Reiterates "Hold" Rating for Sage Therapeutics (NASDAQ:SAGE) - MarketBeat
Sage slips as Huntington’s Disease therapy fails in mid-stage trial - Seeking Alpha
Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again - MarketWatch
Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study - XM
Sage Therapeutics to end Huntington’s disease trial after drug fails again - MarketWatch
Sage Therapeutics' rare disease drug fails mid-stage study - XM
Sage Therapeutics Ends Huntington's Drug Development After Failed Phase 2 Trial | SAGE Stock News - StockTitan
Sage Therapeutics' stock falls after therapy fails for a third time - MarketWatch
CNS Drug Development: Same As It Ever Was (SAGE) - Seeking Alpha
BB Biotech AG's Strategic Acquisition of Sage Therapeutics Shares - GuruFocus.com
FMR LLC Adjusts Stake in Sage Therapeutics Inc - GuruFocus.com
Easterly Investment Partners LLC Sells 91,500 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Acumen Pharma Taps Former Sage Executive to Lead Alzheimer's Drug Development | ABOS Stock News - StockTitan
Sage Therapeutics' SWOT analysis: stock faces challenges amid CNS drug market shifts - Investing.com
Vanguard Group Inc's Recent Transaction in Sage Therapeutics Inc - GuruFocus.com
Objective long/short (SAGE) Report - Stock Traders Daily
Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) sh - GuruFocus.com
Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seekin - GuruFocus.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus.com
Pinnacle Associates Ltd. Has $1.22 Million Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Sage Therapeutics Reports Q3 Growth and Strategic Focus - TipRanks
Sage Prioritizes Zurzuvae For PPD, Ends MDD Effort, Drops Zulresso - Citeline News & Insights
Sage Therapeutics Inc Stock (SAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):